LAZCLUZE has received FDA approval based on positive outcomes from the Phase III MARIPOSA study in non-small cell lung cancer patients. Credit: New Africa/Shutterstock.

Johnson & Johnson has selected Onco360 as pharmacy partner for the distribution of LAZCLUZE (lazertinib).

The medication is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, recently approved for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Its approval, along with that of RYBREVANT (amivantamab-vmjw), is said to offer a chemotherapy-free regimen for patients whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.

Clinical studies have demonstrated that this new treatment regimen provides superior progression-free survival compared to the traditional standard of care.

Manufactured by Janssen Biotech, a division of Johnson & Johnson, LAZCLUZE has received FDA approval based on positive outcomes from the Phase III MARIPOSA study.

See Also:

The study indicated that the combination of RYBREVANT and LAZCLUZE reduced the risk of disease progression or death by 30% compared to osimertinib.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients experienced a nine-month longer median duration of response.

The median progression-free survival (PFS) for patients treated with the combination of RYBREVANT and LAZCLUZE was significantly extended, reaching 23.7 months, as opposed to 16.6 months for those treated with osimertinib.

Onco360 chief commercial officer Benito Fernandez stated: “Onco360 is grateful for the opportunity to partner with the Johnson and Johnson team and become a speciality pharmacy provider for LAZCLUZE.”

“We are proud to add this first-line, chemotherapy-free, targeted therapy to our portfolio to treat patients with locally advanced or metastatic EGFR-mutation non-small cell lung cancer.”